• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Phase 1b/2 trial targets stroma barrier in metastatic pancreatic cancer

    Pancreatic cancer has literally walled itself off for decades from efforts to find an effective drug therapy

    DF/HCC Collaborative RNAi Core offers new services

    The DF/HCC Collaborative RNAi Core is pleased to announce the availability of three new miRNA-targeted libraries and a new laser scanning cytometer

    Trials target abnormal fusion gene in lung cancer

    Non-small cell lung cancer (NSCLC), the most commonly fatal malignancy in the United States, accounts for approximately 85 percent of all lung cancer

    Ovarian cancer research takes center stage

    Most women with ovarian cancer are diagnosed in their 60s and 70s with advanced stage disease that has spread throughout the abdomen

    New Core: Recombinant Protein Expression and Purification

    The Recombinant Protein Expression and Purification (RPrEP) Core was launched in 2009 to provide a cost-effective resource to the DF/HCC community for expression and purification of recombinant fusion proteins necessary for pre-clinical studies as well as for basic mechanistic studies by immunologists and cancer biologists

    Tissue Microarray and Imaging Core

    The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research

    Community Practice Core

    The Community Practice Core (CPC) offers access to a clinical laboratory of over ten million patients within Harvard Vanguard Medical Associates, Harvard Pilgrim Health Care, and the HMO Cancer Research Network

Displaying results 78 to 84 out of 206